Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering personalized cell therapies for solid tumor cancers. Its core technology uses autologous tumor-infiltrating lymphocytes, or TILs, which are immune cells collected from a patient’s tumor, expanded, and administered as an individualized treatment. The company’s marketed products include Amtagvi, a TIL therapy for certain adults with advanced or metastatic melanoma, and Proleukin, an interleukin-2 product used in specified cancer treatment settings. Iovance also develops TIL-based therapies and related technologies for cancers including cervical, endometrial, head and neck, and non-small cell lung cancers, alongside programs addressing selected blood malignancies. Its activities span biopharmaceutical research, cell-therapy manufacturing, clinical development, and commercialization. By applying a patient-specific approach to immune-oncology, Iovance Biotherapeutics, Inc. occupies a specialized role in the cancer therapeutics market, linking advanced cellular medicine with treatment needs that may not be adequately addressed by conventional drug therapies.
Website300 Rouse Blvd.
Philadelphia, PA, 19112
United States
The latest articles about IOVA.
Tipranks Press Release.
Generated by AI
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about IOVA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.